三元基因(837344) - 2023 Q4 - 年度业绩

Financial Performance - The company achieved operating revenue of CNY 244,732,951.33, representing a year-on-year increase of 43.12%[4] - Net profit attributable to shareholders was CNY 31,618,475.66, reflecting a growth of 1.80% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 29,029,800.13, up 40.11% year-on-year[4] - Basic earnings per share increased to CNY 0.26, a rise of 4.00% from the same period last year[4] Assets and Equity - Total assets at the end of the reporting period reached CNY 1,329,439,894.81, marking a 42.43% increase year-on-year[5] - Shareholders' equity attributable to the company was CNY 610,875,325.06, up 6.27% compared to the beginning of the period[5] Growth Drivers - The growth in revenue and net profit was primarily driven by the recovery in demand for medications following the adjustment of national pandemic control policies[7] - The company is advancing its gene engineering drug R&D and production base project, contributing to the increase in total assets[7] - The company has strengthened its sales team and optimized market channels to achieve significant business growth[6] Financial Data Disclaimer - Investors are advised to note that the financial data presented is preliminary and subject to audit, which may result in discrepancies[8]